Figure 1
From: Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
Clinical outcomes of patients. Number of exacerbations within 32 weeks (A, n = 29), percent forced expiratory volume in one second (FEV1) of predicted values (B, n = 25), and dose of oral prednisolone (C, n = 15) before and after initiating treatment with mepolizumab or benralizumab in patients with allergic bronchopulmonary aspergillosis complicated by asthma. Treatment with mepolizumab or benralizumab significantly reduced exacerbation rate and oral corticosteroid dose, and improved pulmonary functions.
